Takeda’s plasma-derived therapies (PDT) business tackles supply-chain challenges to expand access to life-saving treatments, ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

Takeda Pharmaceutical's strong earnings, dividends, and strategic moves make it an appealing investment despite US policy uncertainties. Read my earnings analysis.

Takeda Pharmaceutical said on Thursday its CEO Christophe Weber will retire after more than a decade at the helm of Japan's ...

Pharmaceutical company Takeda is pioneering a technology-enabled, patient-centered future for plasma-derived therapies ...

In line with the "We the UAE 2031" Vision, the summit focused on improving quality of life and advancing specialized care for ...

Takeda Pharmaceutical Co.’s board has selected Julie Kim, the head of the company’s US unit, to replace Christophe Weber as the drugmaker’s new chief executive officer.

Takeda Healthcare Philippines, Inc. and Otsuka-Solar Philippines, Inc., with the support of the Embassy of Japan in the Ph ...

Takeda has announced the appointment of Julie Kim as successor to Christophe Weber, its current president, CEO and representative director, effective from June 2026. The decision was unanimously ...

The Japanese drugmaker said that Kim, president of its U.S. business unit, will succeed Chief Executive Christophe Weber, who plans to retire in June next year.

Takeda has axed plans to seek approval for its failed epilepsy drug candidate soticlestat. The Japanese drugmaker pulled the plug on the program after the FDA pointed out the shortcomings of its ...

Christophe Weber will step down as CEO of Takeda next year, the company announced, following a dropoff in its share price over the last couple of years.